Astrazeneca (AZN) Long-Term Deferred Tax (2009 - 2026)

Astrazeneca's Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $5.6 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 8.24% year-over-year to $5.6 billion; the TTM figure through Mar 2026 stood at $5.6 billion (down 8.24% YoY), while the FY2025 annual figure was $5.8 billion, up 8.83% from the prior year.
• Long-Term Deferred Tax was $5.6 billion for Q1 2026 at Astrazeneca, down from $5.8 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $6.3 billion in Q2 2025 to a low of $3.3 billion in Q4 2022.
• Historically, Long-Term Deferred Tax has averaged $4.8 billion across 5 years, with a median of $4.7 billion in 2023.
• Biggest YoY gain for Long-Term Deferred Tax was 51.44% in 2022; the steepest drop was 24.64% in 2022.
• A 5-year view of Long-Term Deferred Tax shows it stood at $3.3 billion in 2022, then jumped by 44.59% to $4.7 billion in 2023, then gained by 13.33% to $5.3 billion in 2024, then climbed by 8.83% to $5.8 billion in 2025, then retreated by 3.88% to $5.6 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $5.6 billion (Q1 2026), $5.8 billion (Q4 2025), and $6.1 billion (Q3 2025), per Business Quant data.